Investor Webinar Presentation
Released
Released
Announcement PDF
Investor
Webinar
1
Final Phase II Results
Real-World Evidence
ROXUS® U.S. Update
October 2026
Lee Rodne, Executive Chairman
Professor Geoffrey Strange, Chief Medical Officer
Melissa Hadley Barrett, Nurse Practitioner and
Sexologist, Director, Restorative Health Clinic
Professor
Geoffrey Strange
LTR Pharma CMO PhD, FESC,
FCSANZ
‣ Chief Medical Officer, LTR Pharma Ltd
‣ Professor, School of Medicine,
University of Notre Dame Australia
‣ Faculty of Medicine and Health,
The University of Sydney
Melissa
Hadley Barrett
MNurs, PGrad Dip Sexology, PGrad
Dip Mid, GradCertDiab, BSc
‣ Nurse Practitioner and Sexologist,
25+ years
‣ Director, Restorative Health Clinic,
Perth, WA
‣ Leading prescriber of SPONTAN
(ROXUS in the U.S.); lead author of the
147-patient real-world SPONTAN study
Your presenters
Lee
Rodne
LTR Pharma Executive Chairman
‣ Healthcare entrepreneur and executive
with 25+ years’ experience building,
commercialising and scaling healthcare
and technology businesses across public
and private markets.
‣ Former CEO and Managing Director of
Allied Medical, a Fortescue Metals Group
spin-out (later Admedus Ltd, now Anteris
Technologies), which he led from an
approximately $800k valuation to a peak
valuation of approximately $250m.
‣ Track record commercialising medical
products across Australia, North
America, Europe and Asia, including
experience in nasal drug-delivery
products.
Investor Webinar | October 2026 2
Important Notice and Disclaimer
Investor Webinar | October 2026 3
‣ Nature of Document: This presentation has been prepared and issued by LTR Pharma Ltd
(Company or LTP) to provide general information about the Company. The information in this
document is in summary form and should not be relied upon as a complete and accurate
representation of any matters that a reader should consider in evaluating the Company. While
management has taken every effort to ensure the accuracy of the material in this presentation,
the Company have not verified the accuracy or completeness of the material contained in this
presentation.
‣ Not an offer: This presentation is NOT a recommendation, offer or invitation to subscribe for or
purchase LTP securities. This presentation is not exhaustive and does not contain all of the
information a potential investor, or their professional advisers would require, and it does NOT
constitute a “Prospectus" or a "Disclosure Document” (as defined in the Corporations Act 2001
(Cth), and has not been, and will not be, lodged with the Australian Securities and Investments
Commission or any other regulatory authority. This presentation should not be distributed,
transmitted, or viewed by any person in any jurisdiction where the distribution, transmission or
viewing of this document would be unlawful under the securities or other laws of that or any
other jurisdiction. In particular, this presentation may not be released to US wire services or
distributed publicly in the United States. This presentation does not constitute an offer to sell, or
a solicitation of an offer to buy any securities in any jurisdiction. Any failure to comply with such
restrictions could constitute a violation of applicable securities laws.
‣ Not financial product advice: You should not act and should refrain from acting in reliance on this
presentation. Nothing contained in this presentation constitutes investment, legal, tax or other
advice. This presentation does not take into account the individual investment objectives, financial
situation and particular needs of potential investors. Before making a decision to invest in the
Company at any time, you should conduct, with the assistance of your broker or other financial or
professional adviser, your own investigation in light of your particular investment needs,
objectives and financial circumstances and perform your own analysis of the Company before
making any investment decision.
‣ Forward looking statements: This presentation contains forward-looking information about the
Company and its operations. In certain cases, forward-looking information may be identified by
such terms as "anticipates", "believes", “should”, "could", "estimates", “target”, “likely”, “plan”,
"expects", "may", “intend”, "shall", "will", or "would". These statements are based on information
currently available to the Company and the Company provides no assurance that actual results
will meet management's expectations. Forward-looking statements are subject to risk factors
associated with the Company’s business, many of which are beyond the control of the Company.
It is believed that the expectations reflected in these statements are reasonable but they may be
affected by a variety of variables and changes in underlying assumptions which could cause actual
results or trends to differ materially from those expressed or implied in such statements. There
can be no assurance that actual outcomes will not differ materially from these statements.
‣ Disclaimer: No representation or warranty, express or implied, is made by the Company that the
material contained in this presentation will be achieved or proved correct. Except for statutory
liability which cannot be excluded, the Company, its directors, officers, and employees expressly
disclaim any responsibility for the accuracy, fairness, sufficiency or completeness of the material
contained in this presentation and excludes all liability whatsoever (including in negligence) for
any loss or damage which may be suffered by any person as a consequence of any information
in this presentation or any effort or omission therefrom. The Company will not update or keep
current the information contained in this presentation or to correct any inaccuracy or omission
which may become apparent, or to furnish any person with any further information. Any opinions
expressed in the presentation are subject to change without notice.
‣ LTR Pharma Limited ACN 644 924 569
‣ No New Material Information: This presentation contains no new material information;
all information has been previously disclosed in the Company's ASX announcements.
Clinical proof established
‣ SPONTAN / ROXUS is a rapid-acting
intranasal PDE5 therapy. Final Phase II
data confirmed six-fold faster median
absorption than oral vardenafil
(p<0.0001), with a favourable safety
and tolerability profile.¹
‣ Lead program: SPONTAN / ROXUS
Executive Summary
4
Clinical validation → Real-world validation → U.S. prescriptions commenced
Footnotes: 1) Six-fold refers to median Tmax of 10 minutes for SPONTAN 5 mg versus 60 minutes for oral vardenafil 20 mg (p<0.0001); final Phase II Clinical Study Report,
ASX announcement 1 October 2026. 2) ASX announcement 11 August 2026. 3) Appendix 4C for quarter ended 30 June 2026. Cash figures in Australian Dollars.
1
6× faster
median absorption
93% 150,000
Real-world demand validated
‣ A 147-patient Australian TGA SAS
cohort: 93% of men seeking greater
convenience and spontaneity reported
improved erectile hardness and/or
penetration (42 of 45); 68% across the
full cohort.²
‣ Evidence: clinical + patient reported
U.S. prescriptions commenced
‣ ROXUS patient-specific prescription
fulfilment commenced under Shed
and Strive (Oct 2026). The FDA
pharmacokinetic dataset is complete;
pivotal Phase III is targeted for
1H CY2027. $19.6M cash and zero
debt support near-term execution.³
‣ Commercial partners: Shed, Strive, Aptar, Mayne,
EBOS/Symbion
Real-world response
in men seeking
convenience (42 of 45)
Minimum ROXUS prescription
units supported by Shed
2 3
Investor Webinar | October 2026
Men meeting IIEF-5 criteria for ED, by age (%)
≈ 1 in 2
men aged 65+ meet criteria
for ED (48.0% at 65–74,
52.2% at 75+)
Only 7.7%
diagnosed by a provider;
only 16.7% had discussed
erections with one
17.9%
13.3% 12.7%
25.3%
33.9%
48.0%
52.2%
18–24 25–34 35–44 45–54 55–64 65–74 75+
Age group (years). Among men with a prior heart attack or heart failure, about 65% met criteria
for ED; with diabetes 41% and hypertension 40%.
ED in the US: common, age-related, cardiometabolic
2021 National Survey of Sexual Wellbeing: nationally representative sample of 1,822 US men aged 18–87, IIEF-5.
24.2%
of US men aged 18+ meet
IIEF-5 criteria for ED,
about 1 in 4
Investor Webinar | October 2026 5
30 to 120 minutes
to peak
Median Tmax: avanafil 30 min, sildenafil 60 min,
vardenafil 60 min, tadalafil 120 min.
Intimacy has to be planned around the tablet
Food, alcohol
and the gut
A high-fat meal delays and reduces absorption
of sildenafil and vardenafil. Dyspepsia and reflux
are common reasons men avoid daily dosing.
Timing rules add friction to an already
sensitive moment.
First-pass
metabolism
Oral PDE5is are absorbed through the gut and pass
through the liver, where 90 to 95% of the drug
is removed before it reaches the circulation.
Higher doses are needed to reach
therapeutic levels
Agent US brand Usual on-demand dose Route Median Tmax Half-life
Sildenafil Viagra® 25, 50, 100 mg Oral 60 min ~4 h
Vardenafil Levitra® 10, 20 mg Oral 60 min ~4 h
Tadalafil Cialis® 10, 20 mg (5 mg daily) Oral 120 min 17.5 h
Avanafil Stendra® 50, 100, 200 mg Oral 30 min ~5 h
Vardenafil ROXUS® 5 mg (2.5 mg per nostril) Intranasal 10 min ~4 h
PDE5 inhibitors work. Oral delivery is the constraint
Same mechanism the difference is absorption = speed
Sources: Wolfe TR. Not Just a Single Squirt: Understanding Nasal Drug Delivery. EMS Airway, 2022. US prescribing information for Viagra, Levitra, Cialis, Stendra.
Roxus Tmax: Chung et al. 2025; LTR Pharma Phase II final data, 1 October 2026. Half-lives approximate.
Investor Webinar | October 2026 6
Design agreed with FDA at Pre-IND. Final report completes the PK dataset for the planned 505(b)(2) submission.
Comparative PK results Six-fold faster absorption, p<0.0001
Parameter
5 mg 2.5 mg
Vardenafil
20 mg oral
Tmax, median (range) 10 min (10–15) 11 min (5–60) 60 min (30–186)
Cmax (mean ± SD, ng/mL) 8.9 ± 6.8 5.8 ± 4.9 19.8 ± 8.8
Half-life (t½, mean) 4.4 hours 3.8 hours 4.4 hours
Dose-normalised
AUC0-inf (ng·h/mL/mg)
3.6 4.8 3.2
Accumulation ratio
(5 days once daily)
1.0 ± 0.9 n.a. n.a.
SAEs / Grade 3+ TEAEs /
discontinuations
0 0 0
Final Phase II Report Confirms Six-Fold Faster Absorption
and Completes FDA PK Dataset
Investor Webinar | October 2026 7
Key Findings
‣ Six-fold faster absorption than oral vardenafil (p<0.0001)
‣ Approximately dose-proportional exposure;
substantially lower metabolite (M1) exposure than
the oral tablet
‣ No drug accumulation over five days of once-daily
dosing
‣ Comparable pharmacokinetics in men aged 65 and over
(14 of 27)
‣ No SAEs, no Grade 3+ events, no discontinuations;
most frequent treatment-related events nasal
congestion and headache, mild and self-resolving
Final Clinical Study Report | n=27 (14 aged ≥65) | randomised three-way crossover | independent CRO
48.9% Reasons given for stopping
(Carvalheira et al. 2012, n = 160 dropouts)
8.7%
14.4%
17.5%
36.8%
Cardiovascular safety concerns
Erection recovered
Psychological factors (anxiety, fears, beliefs)
Non-effectiveness
Men often stop for a
combination of reasons. The
practical ones, waiting an
hour, empty stomach,
planning around the tablet,
are the ones a faster, food-
independent route can
change.
Half of men stop oral therapy
of 327 men with ED
discontinued oral PDE5
inhibitor treatment
(Carvalheira et al. 2012)
Investor Webinar | October 2026 8
Real-World Cohort: 147 Treatment-Experienced Men
147 treatment-experienced men,
mean age 65.6 years 62% history of prostate cancer;
59% post-prostatectomy 100% previously treated with oral
PDE5 inhibitors
Why men sought SPONTAN®, and the clinical context
102 men
Seeking improved efficacy after
inadequate response to oral therapy
45 men
Seeking greater convenience
and spontaneity
About 50%
Oral PDE5i dropout rates; lack
of spontaneity consistently cited³
Post-prostatectomy context: oral PDE5i response 12–17%
in the first six months²; ED in up to 85% of men¹
Outcome measure: improved erectile
hardness and/or achieving penetration
Source: ASX announcement 11 August 2026. 1) Emanu JC et al., Curr Opin Support Palliat Care 2016;10(1):102-107. 2) Published literature as cited in ASX announcement 11 August 2026. 3) Carvalheira et al., J Sex Med 2012.
Disclosure: The study was supported by an investigator-initiated grant from LTR Pharma. Melissa Hadley Barrett has a paid consulting role with LTR Pharma.
TGA Special Access Scheme | retrospective, single specialist clinic, Jan to Dec 2025 | patient-reported outcomes
Treatment-experienced men seeking either better efficacy or greater spontaneity than oral tablets
provided, assessed on patient-reported outcomes in routine clinical practice.
Investor Webinar | October 2026 9
Real-World Outcomes: Patient-Reported Response
10
93% men seeking greater convenience
and spontaneity (42 of 45) 68%overall cohort (100 of 147)
53% achieved penetration following
treatment (78 of 147)
Composite endpoint by subgroup By reason for seeking treatment and prostatectomy status
57% 58 of 102
Inadequate response to oral PDE5 therapy
64% 56 of 87
Post-prostatectomy subgroup
73%
Non-prostatectomy subgroup
Post-prostatectomy context: oral PDE5i response 12–17% in the first six months²; ED in up to 85% of men¹
Source: ASX announcement 11 August 2026. 1) Emanu JC et al., Curr Opin Support Palliat Care 2016;10(1):102-107. 2) Published literature as cited in ASX announcement 11 August 2026. Disclosure: The study was supported
by an investigator-initiated grant from LTR Pharma. Melissa Hadley Barrett has a paid consulting role with LTR Pharma.
Improved erectile hardness and/or achieving penetration | 147 treatment-experienced men
Highest response among men seeking greater convenience and spontaneity, with encouraging
results in men inadequately served by oral therapy and men following prostatectomy.
44 of 60
Investor Webinar | October 2026
ROXUS® U.S. patient-specific prescription fulfilment has commenced.
ASX announcement 6 October 2026
ROXUS® U.S. Prescriptions Commenced
First valid patient-specific ROXUS® prescriptions fulfilled by Strive through Mavrox
ROXUS® is a compounded medication prepared for an identified individual patient on a valid prescription from a prescribing healthcare practitioner and, as such, is not reviewed or approved by the U.S. Food and Drug
Administration for safety or efficacy. Compounded drugs are intended for patients whose prescriber has determined their medical needs are not met by an available FDA-approved drug.
Demand Engine
Shed Holdings LLC | Executed 17 Jul 2026
US direct-to-consumer telehealth platform: Mavrox
‣ First U.S. commercial route-to-market; first valid patient-specific prescriptions
received through Mavrox and fulfilled
‣ Minimum 150,000 ROXUS® prescription units in the first 12 months from
Commercial Launch, subject to performance
‣ Two-year U.S. DTC telehealth exclusivity from launch, subject to performance
Supply Engine
Strive Specialties Inc. | Executed 20 Jul 2026
Exclusive US 503A pharmacy and fulfilment partner
‣ Five-state 503A platform with nationwide compounding and fulfilment
licensure
‣ Technology transfer and readiness complete; approximately 100,000 Aptar
pump and bottle components received
‣ Two-year exclusivity, subject to performance; LTR retains product ownership,
IP and formulation supply
‣ Moves ROXUS® from U.S. Market preparation
to prescription fulfilment
‣ Capital-light model using established telehealth
and pharmacy infrastructure
‣ First patient-specific prescriptions now being fulfilled
‣ Premium ED positioning without LTR building U.S.
prescribing, pharmacy or fulfilment infrastructure
Investor Webinar | October 2026 11
Cash $19.6M | Avg. quarterly net operating outflow $2.8M¹ | Zero debt |
Funded to deliver near-term U.S. commercial, clinical and regulatory value inflection points
Key Milestones
Investor Webinar | October 2026 12
Completed milestones → current execution → next major value inflection points
‣ U.S. ROXUS® prescription fulfilment
commenced
‣ Final Phase II report completed FDA PK
dataset
‣ 147-patient real-world data reported
‣ Shed and Strive definitive U.S. agreements
executed
‣ FDA Pre-IND alignment
‣ Extractables study completed
‣ EJPS publication
‣ ROXUS® - U.S. prescription activity
– U.S. prescription activity building
following commencement
– Further updates as meaningful
information becomes available
‣ SPONTAN® - Phase III initiation / start-up
activities
– Post-Phase II FDA engagement and IND
preparation
– Site and study start-up activities
‣ SPONTAN® - Submission-enabling
workstreams
– CMC, human factors, leachables and non-
clinical toxicology
‣ OROFLOW® - Study initiation
– HREC approved
– Hospital contract sign-off pending
‣ ROXUS® - U.S. Commercial Scale-Up
– Growing U.S. prescription activity and
revenue contribution
‣ SPONTAN® - First patients enrolled in
pivotal Phase III - 1H CY2027
‣ SPONTAN® - Pivotal Phase III recruitment /
execution
‣ SPONTAN® - U.S. FDA submission
– Targeted 2H CY2027, subject to Phase III
completion and finalisation of the
submission package
‣ SPONTAN® - U.S. licensing / commercial
partnering
‣ OROFLOW® - Initial clinical results
COMPLETED
Achieved
EXECUTE NOW
CY2026 Near-Term Execution
NEXT INFLECTION
1H CY2027+ Development Progression
Source: Appendix 4C for the quarter ended 30 June 2026.1) Average net operating cash outflow per quarter over the twelve months to
30 June 2026. June 2026 quarter net operating outflow: $4.4M. Cash figures in Australian Dollars.
Questions
investors@ltrpharma.com www.ltrpharma.com
Authorised for release by the Board of Directors
Backup slides
For Q&A reference
US Commercialisation: Launch Strategy
15
Today: ROXUS®
Fulfilment Commenced
Revenue shared
across LTR Pharma,
Shed and Strive
under executed
commercial
agreements
12 Months Post Launch
SPONTAN® FDA
Pathway: Pivotal
Phase III – Targeted
1H CY27
U.S. FDA Submission –
Targeted 2H CY27
ROXUS ®
Launch Readiness – Complete:
• Technology transfer, testing and
operational readiness complete
• ~100,000 Aptar device components
received
• First prescriptions fulfilled through
Mavrox
ROXUS ®
Volume and Pricing:
• Shed commitment to support not less
than 150,000 ROXUS® units during the
first 12 months
• LTP anticipates pricing will be in line
with other premium ED competitors
ROXUS ®
Capital-light US Penetration:
• Capital-light market entry for LTR
Pharma
• Shed actively promoting ROXUS® as a
differentiated ED product on their
platform
SPONTAN ®
FDA Approval for Commercial Scale:
• Unlocks pharma licensing
partnerships
• Expands U.S. commercial channels
• Expands the addressable U.S.
opportunity
• Supports scalable long-term U.S
revenue growth
ROXUS® –
first US penetration
SPONTAN® –
delivering commercial scale
Indicative timeline – not to scale
Investor Webinar | October 2026
Portfolio Overview
and Development
Focus
16
Lead Clinical Program ‣ TGA Early Access – ACTIVE
‣ FDA 505(b)(2) regulatory pathway
‣ Phase II PK study complete; final report completes FDA PK
dataset
‣ 503A Commercial partners secured (US)
Early Development
OROFLOW – Platform Expansion
‣ HREC-approved study; initiation pending hospital contract
sign-off
‣ First platform application beyond ED, in gastrointestinal
disease
‣ Capital prioritised to lead program
Strategic Investment
LevOmega
‣ Equity Investment – 43%
‣ Focused on development of nature-identical omega-3
products
‣ Separate development pathway and capital structure
‣ Complementary to LTR’s core intranasal programs
Validated Platform
and Expanding Men’s
Health Portfolio
Intranasal Sprays for Erectile
Dysfunction
Intranasal Spray for
Oesophageal Motility Disorders (OMD)
Nature-Identical omega-3 Products
Portfolio Expansion
KYZATREX®
‣ Exclusive pilot commercialisation agreement with Marius
Pharmaceuticals (US)
‣ FDA-approved oral testosterone therapy; initial Australian
patient access via the TGA Special Access Scheme
‣ Six-month evaluation period, with a right to negotiate an
exclusive Australian licence
Oral Therapy for Testosterone
Deficiency
Investor Webinar | October 2026
ROXUS® - 503A SPONTAN® - 505(b)(2) approval
Rapid commercial launch and market validation Expanded commercial opportunity
✓ Rapid route to initial US revenues through cash-pay
DTC and telehealth channels
Efficient made-to-order manufacturing model with limited
inventory requirements
1 Regulatory protection and intellectual property
505(b)(2) pathway may provide regulatory exclusivity and strengthen
intellectual property protection through potential Orange Book listing
2 Broader commercial reach
FDA-approved labelling supports promotional claims, payer engagement and
potential reimbursement, expanding commercial opportunities
Scalable pharmaceutical supply
Commercial-scale manufacturing supports broader distribution channels and
long-term supply flexibility
Strategic partnering opportunities
An FDA-approved product may enhance licensing, partnering and ex-US
expansion opportunities via dossier
LTR’s phased US strategy is designed to generate near-term commercial momentum while creating the foundation for a significantly larger
long-term value opportunity
Generates commercial experience, physician adoption
and real-world data to support broader strategy
✓ Establishes early physician adoption, prescribing behaviour
and commercial proof points ahead of FDA approval
3
4
Illustrative of the potential benefits of FDA approval. Outcomes are not assured and are subject to regulatory and commercial factors.
✓
✓
✓
US Strategy: What FDA approval unlocks
503A enables rapid commercialisation today, while the FDA approval has the potential to materially
expand the addressable market and long-term commercial opportunity
Investor Webinar | October 2026 17
Oral PDE5 inhibitors remain first-line, but response and persistence limitations leave a sizeable unmet need
~US$5B
estimated annual global
ED drug market¹
~322M
men globally estimated
to have ED in 2025¹
Treatment pathway and gap
Rapid-onset,
non-invasive PDE5 option
‣ Positioned across the broad ED market
‣ Supports patients seeking greater
spontaneity
‣ Provides a non-invasive option for
patients inadequately served by oral
therapy
‣ Positioned before invasive treatments
1) Frost & Sullivan, The Erectile Dysfunction Medicines Market, September 2023. 2) McMahon et al., BMJ 2006. 3) Gillman & Chung, ANZ Journal of Surgery 2026 (MBS data 1996–2024; in-
office, MBS-billed procedures only).
Large ED Market with a Clear Treatment Gap
Oral PDE5 inhibitors
First-line therapy; delayed onset
and high discontinuation
1
30–35% inadequate response
Higher failure rates in difficult-
to-treat populations²
2
Invasive second-line options
Intracavernosal injection utilisation
has fallen >55-fold from peak³
3
Investor Webinar | October 2026 18
Share your feedback
Discover